Ftse Mib
33.607,14
-2,15%
DAX
19.033,64
-2,14%
S&P 500
5.983,99
-0,29%
NASDAQ
19.281,40
-0,09%
Bitcoin
88.250,54
0,37%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Incyte Corporation (INCY) Incyte Corporation (INCY) Notizie

Incyte Corporation

INCY
80,58
-0,95 (-1,17%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 00:32:20
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
08/11/202418:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202422:30BWIncyte Reports Inducement Grants Under Nasdaq Listing Rule..
06/11/202422:15EDGAR2Form 144 - Report of proposed sale of securities
30/10/202413:00BWIncyte to Present at Upcoming Investor Conferences
29/10/202421:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
29/10/202412:05EDGAR2Form 8-K - Current report
29/10/202412:00BWIncyte Reports 2024 Third Quarter Financial Results and..
24/10/202420:03BWIncyte Named One of Top 5 Companies on Science Magazine’s..
21/10/202422:11EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
15/10/202414:30GLOBEKnight Therapeutics Announces Approval of Minjuvi®..
10/10/202415:15BWIncyte Furthers Commitment to People Living with Atopic..
08/10/202414:00BWIncyte to Report Third Quarter Financial Results
08/10/202405:08BWIncyte Reports Inducement Grants Under Nasdaq Listing Rule..
04/10/202418:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202422:30BWIncyte Reports Inducement Grant Under Nasdaq Listing Rule..
03/10/202419:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202419:24EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/10/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/10/202419:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/10/202419:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202402:20BWMehrere brandaktuelle Datenpräsentationen aus dem..
25/9/202413:00BWMultiple Late-Breaking Data Presentations from Incyte’s..
18/9/202423:15PRNUSIncyte and Syndax Announce New England Journal of Medicine..
16/9/202419:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/9/202419:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/9/202400:36BWRetifanlimab (Zynyz®) von Incyte verlängert..
15/9/202407:34BWIncyte’s CDK2 Inhibitor INCB123667 zeigt vielversprechende..
15/9/202406:48BWLe rétifanlimab (Zynyz®) d’Incyte prolonge la survie sans..
14/9/202418:45BWIncyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence..
14/9/202416:30BWIncyte’s Retifanlimab (Zynyz®) Extends Progression-Free..
13/9/202422:06EDGAR2Form 144 - Report of proposed sale of securities
12/9/202422:17EDGAR2Form 144 - Report of proposed sale of securities
09/9/202422:30BWIncyte Reports Inducement Grants Under Nasdaq Listing Rule..
21/8/202422:49BWIncyte präsentiert bahnbrechende Phase 3-Ergebnisse für..
21/8/202417:40BWIncyte to Present Late-Breaking Phase 3 Results for..
16/8/202411:59BWIncyte gibt positive Topline-Ergebnisse der Pivotalstudie..
16/8/202411:46BWIncyte annonce des résultats positifs de l'étude pivot sur..
15/8/202422:30BWIncyte Announces Positive Topline Results from Pivotal Study..
15/8/202422:15BWIncyte und Syndax melden FDA-Zulassung von Niktimvo™..
15/8/202412:26BWIncyte et Syndax annoncent l’approbation par la FDA..
14/8/202423:34BWIncyte and Syndax Announce U.S. FDA Approval of Niktimvo™..
14/8/202421:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/8/202414:00BWIncyte to Present at Upcoming Investor Conferences
12/8/202422:39EDGAR2Form 144 - Report of proposed sale of securities
07/8/202423:00BWIncyte Reports Inducement Grants Under Nasdaq Listing Rule..
30/7/202413:15EDGAR2Form 8-K - Current report
30/7/202413:00BWIncyte Reports 2024 Second Quarter Financial Results and..
29/7/202421:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/7/202422:09EDGAR2Form 144 - Report of proposed sale of securities
24/7/202420:20EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
Apertura: 81,55 Min: 80,20 Max: 82,02
Chiusura: 81,53

La tua Cronologia

NASDAQ
INCY
Incyte
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network